文献速递新发突发、热带与寄生虫病

吡咯烷啶:其在疟疾治疗中的临床药理学综述

Pyronaridine: a review of its clinical pharmacology in the treatment of malaria.
PubMed 文献 · J Antimicrob Chemother · 2023-01-01

吡咯烷啶-青蒿琥酯在2022年WHO疟疾治疗指南更新中被强烈推荐,成为最新的青蒿素联合疗法之一,用于无并发症的恶性和间日疟原虫疟疾。本综述全面概述了吡咯烷啶的临床药理学,包括其作用机制、药代动力学特征及在特殊人群中的研究局限。

要点

  • 吡咯烷啶-青蒿琥酯被2022年WHO指南强烈推荐用于无并发症恶性疟和间日疟。
  • 吡咯烷啶通过干扰疟原虫消化泡内疟色素合成发挥抗疟作用。
  • 吡咯烷啶临床药代动力学知识有限,尤其在儿童和孕妇等特殊人群中。

核心结论

  • 吡咯烷啶-青蒿琥酯成为最新的青蒿素联合疗法,被2022年WHO指南强烈推荐用于无并发症的恶性疟和间日疟。

研究设计与样本

  • 综述,检索范围未明确报告。

主要发现

  • 吡咯烷啶使用超过50年,作为血液裂殖体杀灭剂,通过干扰疟原虫消化泡内疟色素合成发挥抗疟活性。
  • 吡咯烷啶因在血细胞中蓄积而具有高血-血浆分布比,该特征被认为对其药代动力学特性和药理活性至关重要。
  • 吡咯烷啶的药代动力学特征包括口服吸收迅速、分布容积大和总清除率低,导致终末表观半衰期长。
  • 健康志愿者和疟疾感染患者之间观察到药代动力学特征差异,提示疾病可能影响药代动力学特性。
  • 尽管使用历史悠久,对吡咯烷啶的临床药代动力学和药效学知识有限,尤其在儿童和孕妇等特殊人群中。

关键数值与推荐

  • 2022年WHO疟疾治疗指南更新中强烈推荐吡咯烷啶-青蒿琥酯。
  • 吡咯烷啶-青蒿琥酯有片剂和儿童颗粒剂型。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 对吡咯烷啶的临床药代动力学和药效学知识有限,尤其在儿童和孕妇等特殊人群中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pyronaridine-artesunate was recently strongly recommended in the 2022 update of the WHO Guidelines for the Treatment of Malaria, becoming the newest artemisinin-based combination therapy (ACT) for both uncomplicated Plasmodium falciparum and Plasmodium vivax malaria. Pyronaridine-artesunate, available as a tablet and paediatric granule formulations, is being adopted in regions where malaria treatment outcome is challenged by increasing chloroquine resistance. Pyronaridine is an old antimalarial agent that has been used for more than 50 years as a blood schizonticide, which exerts its antimalarial activity by interfering with the synthesis of the haemozoin pigment within the Plasmodium digestive vacuole. Pyronaridine exhibits a high blood-to-plasma distribution ratio due to its tendency to accumulate in blood cells. This feature is believed to play a crucial role in its pharmacokinetic (PK) properties and pharmacological activity. The PK characteristics of pyronaridine include rapid oral absorption, large volumes of distribution and low total body clearance, resulting in a long terminal apparent half-life. Moreover, differences in PK profiles have been observed between healthy volunteers and malaria-infected patients, indicating a potential disease-related impact on PK properties. Despite a long history, there is only limited knowledge of the clinical PK and pharmacodynamics of pyronaridine, particularly in special populations such as children and pregnant women. We here provide a comprehensive overview of the clinical pharmacology of pyronaridine in the treatment of malaria.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Chu WY, Dorlo TPC. Pyronaridine: a review of its clinical pharmacology in the treatment of malaria. J Antimicrob Chemother. 2023. PMID: 37638690. doi:10.1093/jac/dkad260

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。